Tiger Aesthetics Medical

What Tiger Aesthetics Medical does

Tiger Aesthetics Medical, LLC is a privately held medical aesthetics company and wholly owned subsidiary of Tiger Biosciences (based in Conshohocken, PA), with operating headquarters and manufacturing in Franklin, WI. Founded in 2024 through a roll-up of acquired assets, the company assembles, develops, and commercializes a head-to-toe portfolio of regenerative aesthetics products serving board-certified plastic and cosmetic surgeons (via its BioBody division), dermatologists, and medical spas (via its BioDerma division). The portfolio spans structural adipose tissue (alloClae, with dermaClae planned for 2027), silicone gel breast implants and tissue expanders (Sientra, AlloX2, Dermaspan), a biostimulatory dermal filler (Bellafill), absorbable sutures for facial lifting (Silhouette Instalift), an enhanced-viability fat transfer system (Viality with AuraClens surfactant), a single-use cellulite reduction device (Avéli), a no-touch implant delivery device (Tiger Guard), and a PRP platform (Amplifine).

The company's underlying technology combines FDA-regulated human cell and tissue processing (HCT/P) for allogeneic adipose products with conventional Class III medical device engineering for implants and instruments. Notable technical differentiators include alloClae's intact-adipocyte architecture with terminal sterilization to a 10⁻⁶ SAL, Sientra's proprietary HSC/HSC+ high-strength cohesive gel with 10-year prospective safety data, the Viality system's surfactant-enhanced fat cell survival (>80% retention at 12 months), and the AlloX2 expander's integrated-drain dual-port design. The business model is predominantly transactional hardware and tissue product sales to licensed medical practitioners via a direct field sales force, with no direct-to-consumer distribution; pricing varies by procedure complexity (e.g., alloClae procedures range from $10,000 to $100,000 per treatment) and is ultimately set by individual providers. Revenue is supplemented by recurring practitioner relationships supported through clinical education, warranty programs (including the Sientra Platinum20 20-year warranty), and provider-locator tools on product-specific websites that drive patient referrals to stocking practices.

Name

Tiger Aesthetics Medical

Legal name

Tiger Aesthetics Medical, LLC

Website

https://tiger-aesthetics.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

101–250 employees

Short description

Tiger Aesthetics Medical is a privately held medical aesthetics company and subsidiary of Tiger Biosciences that develops, manufactures, and sells a head-to-toe portfolio of regenerative aesthetic products — including structural adipose tissue (alloClae), breast implants (Sientra), fillers (Bellafill), and devices (Avéli, Viality, Tiger Guard) — to plastic surgeons, dermatologists, and MedSpas via a direct field sales force.

Ownership category

akta.pro rank

Product category

Medical Aesthetic Devices & Regenerative Tissue Products

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Regenerative aesthetics
• Medical aesthetic devices
• Breast implants
• Dermal fillers
• Fat transfer systems

Headquarters

HQ city

Franklin

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Medical Device & Aesthetic Product Sales: Tiger Aesthetics generates revenue through the sale of medical devices and tissue products to aesthetic practitioners. Products are sold directly through the company's sales force to board-certified plastic surgeons, dermatologists, and MedSpas. The portfolio includes breast implants, tissue expanders, dermal fillers, PRP systems, fat transfer devices, and implantable devices. Revenue is predominantly one-time transactional per unit/device sold to practitioners, though the company has recurring customer relationships through its support and warranty programs (e.g., Sientra Platinum20 20-year warranty).
2. Allogeneic Tissue Product Sales (alloClae): Revenue from the commercial sale of alloClae structural adipose tissue, a human allograft derived from processed cadaver fat. alloClae is distributed to licensed aesthetic practitioners for use in body contouring procedures. The product launched commercially in 2025 and has experienced rapid adoption, with initial supply shortages and procedures costing between $10,000 and $100,000 per treatment.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Tiger Aesthetics Medical develops, manufactures, and sells a head-to-toe portfolio of regenerative aesthetics and reconstructive medical products to licensed aesthetic practitioners. The portfolio spans structural adipose tissue products (alloClae), silicone gel breast implants and tissue expanders (Sientra, AlloX2, Dermaspan), biostimulatory dermal fillers (Bellafill), fat transfer systems (Viality), absorbable facial sutures (Silhouette Instalift), PRP platforms (Amplifine), a no-touch implant delivery device (Tiger Guard), and an FDA-cleared cellulite reduction device (Avéli). Products are administered exclusively by qualified medical providers and sold through a direct, two-division field sales organization.

Product overview

Tiger Aesthetics Medical operates as a diversified medical aesthetics company offering a head-to-toe portfolio of regenerative aesthetics and reconstruction products. The portfolio includes structural adipose tissue products (alloClae™ for body contouring, with dermaClae™ forthcoming for facial applications), silicone gel breast implants and tissue expanders (Sientra brand), aesthetic devices (Avéli™ for cellulites, Tiger Guard™ delivery device), dermal and biostimulatory fillers (Bellafill®), fat transfer technologies (Viality™ system), thread lifts (Silhouette Instalift®), and PRP systems (Amplifine™). The company has pursued an aggressive acquisition strategy, acquiring Sientra (2024), Suneva Medical product lines including Bellafill and Silhouette Instalift (2024), and Revelle Aesthetics with Avéli (2024). As a wholly owned subsidiary of Tiger Biosciences, Tiger Aesthetics combines its HCT/P (Human Cell and Tissue Products) expertise with medical devices to serve both cosmetic and reconstructive surgery markets.

Differentiator

Problem solved

Functional benefit

Brands

• alloClae: The first Structural Adipose Tissue designed for use in aesthetic body procedures
• Sientra
• Bellafill
• Avéli
• Viality
• Tiger Guard
• Silhouette Instalift
• Amplifine
• AlloX2
• Dermaspan
• BioBody
• BioDerma

Products and services

• alloClae Structural Adipose Filler The first structural adipose tissue product designed for aesthetic body procedures, composed of intact adipocytes and extracellular matrix from donor-derived adipose tissue. Provides cushioning, volume, and support for breast and body contouring procedures without requiring fat harvesting from the patient. Distributed to licensed plastic surgeons and MedSpas for body contouring applications.
• Avéli Cellulite Treatment FDA-cleared minimally invasive single-use device that identifies and releases the specific fibrous septa causing cellulite dimples in the buttocks and thighs, with real-time confirmation of release during the procedure. Provides long-term reduction in the appearance of cellulite in a single in-office treatment for adult women. Acquired from Revelle Aesthetics in 2024 and available in more than 700 aesthetic practices.
• Bellafill Biostimulatory Filler Longest-lasting FDA-approved dermal filler, combining collagen gel for immediate correction with PMMA microsphere technology that stimulates the body's own natural collagen production for results lasting up to 5 years. The only FDA-approved dermal filler to safely and effectively treat acne scars, with 87% patient satisfaction in 5-year study and 12-year post-market surveillance showing a 0.11% adverse event rate. Acquired from Suneva Medical in October 2024.
• Viality Enhanced Viability Fat Transfer System The only FDA-cleared fat transfer system with a surfactant (AuraClens) shown to enhance survival of fat cells. Uses a 200-micron mesh filter and super-absorbent foam to process lipoaspirate in under 10 minutes, achieving greater than 80% average fat retention at 3, 6, and 12 months in a multi-center prospective clinical study. Used by plastic surgeons and dermatologists for fat grafting procedures.
• Sientra Silicone Gel Breast Implants Silicone gel breast implants with proprietary High Strength Cohesive Gel (HSC/HSC+) offering the highest level of fracture resistance while maintaining a soft, natural feel. Features flat-back design, stronger gel-shell integration, and demonstrated safety through prospective 10-year clinical data. First shaped implant to market in the U.S., first 5th-generation HSC gel, and only company offering a no-cost 20-year Platinum20 warranty. Acquired from Sientra, Inc. in April 2024 and sold to board-certified plastic surgeons.
• Tiger Guard Implant Delivery Device Sterile, single-use delivery device for gel breast implants employing a No-Touch delivery technique that may reduce post-operative complications, allow for smaller incisions than classic insertion techniques, and reduce surgery time. Universal across gel breast implants and used by plastic surgeons in breast augmentation and reconstruction.
• AlloX2 Breast Tissue Expander The first and only breast tissue expander with an integrated dual-port design and drain, enabling immediate, direct, nonsurgical access to the periprosthetic space for serous fluid drainage and diagnostic fluid sampling without altering expander characteristics. AlloX2 Pro is the first FDA-cleared MRI-conditional breast tissue expander paired with Tiger's first FDA-cleared electronic port finder. Used by plastic surgeons in breast reconstruction.
• Dermaspan Breast Tissue Expander Soft shell, single-port breast tissue expander with refined design features 6 suture tabs in a 360-degree orientation. Engineered to enable a gentler, more predictable expansion and more comfortable patient experience. Used by plastic surgeons in breast reconstruction.
• Silhouette Instalift Absorbable Thread The first absorbable suture FDA-cleared for cosmetic facial procedures. Uses Micro Suspension Technology with PLGA micro cones placed in the deepest layer of mid-facial skin to deliver an immediate lift while gradually restoring lost facial volume by activating natural collagen production. Acquired from Suneva Medical in October 2024 and administered by dermatologists and plastic surgeons for facial rejuvenation.
• Amplifine PRP Platform A 510(k)-cleared PRP (Platelet Rich Plasma) preparation platform that delivers ideal platelet concentrations at the point of care, achieving 81% platelet yield, up to 5x platelet concentration, up to 94% removal of WBCs, and ≤0.1% RBCs remaining. Available in 6.5 mL and 15.6 mL formats with short processing times. Acquired from Suneva Medical in October 2024 and used by dermatologists, plastic surgeons, and MedSpas.

Quantifiable outcome

• Greater than 80% average fat retention at 3, 6, and 12 months for Viality fat transfer system
• +6 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Two partnerships are on record, tiered core and minor.

• GenesisTissue Inc.coreStrategic or Co-development Partner · 3 November 2025Tiger Aesthetics made a strategic investment in GenesisTissue Inc., an early-stage biotechnology company developing personalized 3D bioprinted scaffolds for breast reconstruction. GenesisTissue's degradable bioprinted scaffold provides mechanical support for autologous or allogeneic fat transfer as an alternative to silicone implants, with the goal of enabling fully natural breast reconstruction. The partnership aligns with Tiger's tissue engineering and regenerative therapies vision and complements the existing alloClae structural adipose tissue product.
• Mission Plasticos — Reshaping Lives: Full CircleminorStrategic or Co-development PartnerTiger Aesthetics supports the Reshaping Lives: Full Circle program, a partnership with Mission Plasticos focused solely on breast reconstructive surgery for post-mastectomy women living in poverty. This charitable initiative is part of Reshaping Lives America, the first large-scale nationwide program providing no-cost reconstructive care to women in the US living in poverty.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• AbbVie (Allergan Aesthetics): AbbVie's aesthetics division (formerly Allergan) is the global leader in medical aesthetics with breast implants, dermal fillers (Juvederm), and biostimulators. Direct competitor to Tiger Aesthetics across breast implant (Natrelle), filler (Bellafill competitor), and regenerative aesthetics categories.
• Galderma: Global dermatology-focused aesthetics company offering the Sculptra biostimulator, Restylane fillers, and a growing portfolio in regenerative aesthetics. Direct competitor to Tiger's Bellafill biostimulatory filler and broader dermatology channel products sold through BioDerma.
• Mentor (Johnson & Johnson MedTech): Johnson & Johnson's breast aesthetics business, one of the two dominant players in the US breast implant market alongside Allergan. Direct competitor to Sientra silicone gel implants with comparable warranty programs and surgeon relationships.
• Cynosure (Hologic): Medical aesthetics device company offering laser, RF, and energy-based devices for body contouring, skin revitalization, and cellulite treatment. Indirect competitor to Avéli in the body aesthetics category with overlapping MedSpa channel.

Direct peers

• Establishment Labs: Public aesthetics company (NASDAQ: ESTA) focused on breast implant technology with Motiva implants. Direct competitor in the breast implant and reconstruction market, emphasizing safety, innovation, and unique implant features similar to Sientra's positioning.
• GC Aesthetics: Global medical device company specializing in breast implants and aesthetic surgery products with a presence in over 80 countries. Direct competitor in the breast implant segment alongside Sientra within Tiger Aesthetics' BioBody division.
• Revance Therapeutics: Aesthetics-focused company selling the RHA collection of dermal fillers and the DAXXIFY neuromodulator, now expanding into biostimulators and regenerative aesthetics. Direct competitor to Tiger Aesthetics' facial aesthetics and dermal filler offerings.
• InMode: Medical aesthetics device company selling minimally invasive and surgical platforms for body contouring, skin tightening, and fat reduction (e.g., BodyTite, Morpheus8). Competes with Avéli in body aesthetics and indirectly with Tiger's regenerative body portfolio.
• Evolus: Aesthetics company focused on the Jeuveau neuromodulator with growing pipeline in dermal fillers. Direct competitor in the dermatology/MedSpa channel served by Tiger's BioDerma division, targeting similar aesthetic practitioners.
• Sinclair Pharma: Aesthetic specialty pharma company known as the original developer of Silhouette Instalift (now acquired by Tiger Aesthetics via Suneva). Direct comparable in regenerative aesthetics and facial lifting products sold through dermatology and plastic surgery channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tigeraesthetics
• Instagraminstagram.com/tigeraestheticsmedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tiger Aesthetics Medical